MedTrace Logo

Use of Amphetamine-type Stimulants & Its Relationship With HIV Incidence and Antiretroviral Adherence Among MSM and TG

NCT03198962 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 510

Last updated 2023-02-17

No results posted yet for this study

Summary

There are two stages in the study. In Stage 1, 2000 Thai MSM, MSW and TGW/TGSW will be screened at the Thai Red Cross Anonymous Clinic (TRCAC) or Besides walk-in clients of TRCAC, potential participants could be referred to TRCAC by Rainbow Sky Association of Thailand (RSAT), Service Workers In Group (SWING) Foundation and Sisters Foundation. Each participant will complete a short standardized questionnaire on risk behavior, including use of amphetamine-type stimulants (ATS) and other drugs. HIV testing will be done following usual HIV testing and counseling (HTC) guidelines. Stage 1 will collect data on ATS use in the community. The results from stage 1 will also be used to stratify participants for inclusion in stage 2 of the study.

Participants from the screening will be invited to participate in stage 2 of the study, which is the longitudinal cohort study. Recruitment will be stratified by HIV status and ATS use as listed in to ensure an adequate number of ATS users for data analysis. Participants in stage 2 will follow-up every 6 months for 18 months.

Conditions

  • HIV Infections

Sponsors & Collaborators

  • amfAR, The Foundation for AIDS Research

    collaborator OTHER

  • TREAT Asia

    collaborator UNKNOWN

  • Thai Red Cross AIDS Research Centre

    lead OTHER

Principal Investigators

  • Nittaya Phanuphak, MD, PhD · Thai Red Cross AIDS Research Centre (TRCARC)

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-15
Primary Completion
2022-11-15
Completion
2023-02-16

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03198962 on ClinicalTrials.gov